Many of the accountable care organization (ACO) models are being tested to find changes to make to the Medicare Shared Savings Program, but there is a general problem with short-lived models ending and being replaced by new ones, said Michael Chernew, PhD.
Many of the accountable care organization (ACO) models are being tested to find changes to make to the Medicare Shared Savings Program, but there is a general problem with short-lived models ending and being replaced by new ones, said Michael Chernew, PhD, Leonard D. Schaeffer Professor of Health Care Policy and director of the Healthcare Markets and Regulation Lab at Harvard Medical School; chair of the Medicare Payment Advisory Commission; and co-editor-in-chief of The American Journal of Managed Care®.
Transcript:
CMS has been testing ACO models for years now. Will the testing ever be over or is the continuous testing of new models the purpose?
There is something permanent in place: the Shared Savings Program. And the way I think of a lot of this testing is to think of things that might move into the Shared Saving Program, overall. So, I'm not sure the health care system will ever not be learning. I do think it's important for them to build models that don't get tested, and then sunsetted, and they have to put in place replacements.
And I think that's been a general problem in this paradigm, which is the models of limited lifespans, and when they sunset—if they sunset—they need to develop a successor model. You've seen a lot of that: CHART [Community Health Access and Rural Transformation Model] was the successor to AIM [ACO Investment Model]. And the direct contracting, in some way, was the successor to the Next Gen [Next-Generation ACO Model]; Next Gen, in many ways was the successor to Pioneer [ACO Model].
And that sequencing of successor models, I think, has created some churn and uncertainty in the system. And I think they will work increasingly, to build some of the things they learn into the Medicare Shared Savings Program, which was created in statute in the [Affordable Care Act] and doesn't really fit this same testing-diffusion paradigm.
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
As Claims Denials Surge, AI and Data-Driven Insights Equip Clinicians, Hospitals to Fight Back
March 13th 2025As health care costs continue to rise and the burden of chronic disease grows, data-driven insights will be essential in shaping the future of patient care, according to experts from Komodo Health and SmarterDx.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More